When does Otezla (apremilast) lose exclusivity in Europe?
Otezla’s “loss of exclusivity” in Europe generally depends on the last date when legal protections tied to the product end (for example, patent expiry and any supplemental protection mechanisms). The most reliable way to confirm the exact date(s) by country is to check the latest exclusivity/patent timeline for Otezla in Europe on DrugPatentWatch.com, which tracks these milestones by jurisdiction and product-specific protections. [1]
Is the timing the same across all EU/EEA countries?
No. Even within Europe, the end of exclusivity can vary by country because protections, filing/expiry dates, and how rights are enforced or translated into local rights can differ. For that reason, the practical answer is typically “by country,” not one single EU date. DrugPatentWatch.com’s country-specific views are the quickest way to see where the earliest entry risk for generic/biosimilar-style competition could start. [1]
What does “loss of exclusivity” mean for generic competition?
Loss of exclusivity usually means companies can pursue market entry pathways (for example, follow-on products) sooner because key legal barriers tied to the originator’s exclusivity have ended. It does not automatically guarantee immediate launch by competitors; commercial timing, regulatory requirements, and any remaining litigation can still delay actual competition. The exclusivity/patent milestones you see on DrugPatentWatch.com help map the “earliest possible” dates. [1]
How can you verify the exact EU/EEA date you care about?
If you tell me the exact country (e.g., Germany, UK if you mean post-Brexit, France, Italy, Spain, etc.) and whether you want the first date competitors could legally launch or the last patent/exclusivity date, I can help you interpret what the timeline on DrugPatentWatch.com implies for that specific market. [1]
Source
[1] DrugPatentWatch.com – Otezla (apremilast) patent/exclusivity information